Oral cancer patients experience of follow up care

e17002 Background: Oral cancer is one of the most common cancers in India. Uroporphyrinogen decarboxylase (UROD), a key regulator of heme biosynthesis, has recently been suggested as a novel tumor-selective radiosensitizing target against head and neck cancers. Further, a recent study has suggested that tumors with UROD expression may have poorer outcomes and higher rates of recurrence. We tested the expression of UROD splice variants in oral cancer patients who were treated in our hospital to study its expression and impact on the patients. Methods: The expression of both coding and noncoding splice variants of UROD gene was tested in 42 patients (31 male, 11 female) with oral cavity squamous cell carcinomas treated in 2011-12. Pretreatment tumor biopsies were collected and mRNA was extracted using Quiagen RNeasy kit method. cDNA was synthesized using Superscript III and subjected for UROD expression using specific primers. UROD expression and clinical data of patients were analyzed using IBM SPSS 20 Software. Results: The mean age of the patients was 52 years (range 32-70). Buccal mucosa (n=17) and tongue (n=13) were the most common subsites. Seventy six percent had locally advanced disease (T3/T4 and node-positive) and high-grade (70%) cancers. Chemoradiotherapy (CRT) (n =25) and chemotherapy (CT) (n = 10) was given in 35 patients of which 5 had progressive disease. The mean follow up was 11 months. Thirty seven patients were operated, 5 developed locoregional recurrence and 2 developed spine metastases and died during follow-up. UROD was expressed in 23 (54.8%) patients (coding variant = 52.8%, noncoding = 26%). There was no correlation between UROD expression and age, sex, subsite, stage, grade or node positivity. Patients with UROD expression had a slightly poorer response to CRT/CT (30.4% vs 24.1%; p =NS). Similarly, though they had a slightly higher incidence of recurrence, the difference was not significant. Both patients with spinal recurrence had UROD expression. Conclusions: UROD is highly expressed in oral cancer patients in India. Its proposed radiosensitizing and prognostic role in treatment and outcomes though promising needs further evaluation in a larger number of patients.

Download Full-text

Rehabilitation by means of osseointegrated implants in oral cancer patients with about four to six years follow-up

Journal of Oral Rehabilitation ◽

10.1111/j.1365-2842.2005.01551.x ◽

2006 ◽

Vol 33 (3) ◽

pp. 170-174 ◽

Cited By ~ 15

Author(s):

J. SEKINE ◽

K. SANO ◽

H. IKEDA ◽

T. INOKUCHI

Keyword(s):

Oral Cancer ◽

Cancer Patients ◽

Osseointegrated Implants ◽

Oral Cancer Patients

Download Full-text

Efficacy of zinc sulfate on concurrent chemoradiotherapy induced taste alterations in oral cancer patients: A double blind randomized controlled trial

Pakistan Journal of Medical Sciences ◽

10.12669/pjms.35.3.503 ◽

2019 ◽

Vol 35 (3) ◽

Author(s):

Asma Hayat Khan ◽

Jawad Safdar ◽

Saad Uddin Siddiqui

Keyword(s):

Oral Cancer ◽

Cancer Patients ◽

Zinc Sulfate ◽

Concurrent Chemoradiotherapy ◽

Controlled Trial ◽

Detection Threshold ◽

P Value ◽

Double Blind ◽

Oral Cancer Patients

Objectives: To observe the efficacy of zinc sulfate on taste alterations in oral cancer patients receiving concurrent chemotherapy with radiotherapy. Methods: Seventy patients were randomly assigned to both intervention and control group at Oncology Section of Atomic Energy Medical Centre Karachi from September 2017 to March 2018. One group received zinc sulfate capsules (50 mg TDS daily after meals) and the other group received placebo (thrice after meals). Patients were advised to start taking capsules on the first day of their chemoradiation. Both the groups continued the capsules a month after their CCRT ended. Results: Sweet taste was most effected by cancer and its treatment followed by bitter and salty taste. Sour taste was least effected. When both the groups were compared for four tastes for detection threshold, the differences in observation at 3 stages of median IQR were not significant. For recognition threshold between zinc sulfate and placebo, no significant difference was observed in median IQR for salty taste and bitter taste. However, sweet taste (baseline p-value 0.245, end p-value 0.010, follow-up p-value 0.038) was statistically significant at end of CCRT and follow-up stage and sour taste (baseline p-value 0.24, end p-value 0.006, follow-up p-value 0.898) at end of CCRT only. Conclusion: Zinc sulfate was not found to be beneficial in preventing chemoradiation induced taste alterations. Taste and smell alterations are common in patients with cancer and do not receive sufficient support to manage taste alterations. This area requires more research to develop a comprehensive understanding of the nature and its management. Abbreviations: CCRT = Concurrent chemoradiotherapy. DT = Detection threshold. RT = Recognition threshold. AEMC = Atomic Energy Medical Centre. doi: https://doi.org/10.12669/pjms.35.3.503 How to cite this:Khan AH, Safdar J, Siddiqui SU. Efficacy of zinc sulfate on concurrent chemoradiotherapy induced taste alterations in oral cancer patients: A double blind randomized controlled trial. Pak J Med Sci. 2019;35(3):---------. doi: https://doi.org/10.12669/pjms.35.3.503 This is an Open Access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/3.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Download Full-text